Regulatable chimeric antigen receptor

US11578130B2 · kind B2 · utility

Assignees

• Novartis AG · CH
• The Trustees of the University of Pennsylvania · US

Inventors

• Jennifer Brogdon · Cambridge, US
• Boris Engels · Arlington, US
• David Glass · Cambridge, US
• Brian Granda · Cambridge, US
• John Hastewell · Cambridge, US
• Andreas Loew · Somerville, US
• Joan Mannick · Cambridge, US
• Michael C. Milone · Cherry Hill, US
• Leon Murphy · Cambridge, US
• William R. Sellers · Sharon, US
• Huijuan Song · Shanghai, CN
• Brian Edward Vash · Cambridge, US
• Jan Weiler · Cambridge, US
• Qilong Wu · Shanghai, CN
• Li Zhou · Cambridge, US

Key dates

• Filing date: Dec 5, 2018
• Grant date: Feb 14, 2023
• Expiry date: May 16, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/70
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.